PTGX(PTGX)
PTGX
9/21/26
Protagonist Therapeutics (PTGX)
Monday
6:42 PM
ThesisRecent clinical trial delays and increased competition have led to a cautious outlook among investors, impacting stock sentiment negatively.
Revenue Outlook
What Moves the Stock
- 01Clinical trial results for PTG-300 and other candidates
- 02Partnership announcements with larger pharmaceutical firms
- 03Regulatory approvals from the FDA
- 04Market adoption rates of approved therapies
- 05Clinical trial revenues - 100%
- 06Advancements in peptide therapeutics
- 07Increased focus on rare disease treatments
FY2025 Snapshot
- Revenue
- $46M
- Rev. Growth
- -89.4%
- Gross Margin
- 97.3%
- Op. Margin
- -344%
- Net Margin
- -283%
- Net Income
- $-130M
- NI Growth
- -147%
- EPS
- $-2.05
- 1Y Return
- +133%
PTGX Chart
My Notes
- "Management emphasized the need for strategic partnerships to navigate the competitive landscape."
- Moat: The company has a strong intellectual property portfolio that provides a competitive edge but faces risks from larger competitors.
- growth - Investors looking for high-risk, high-reward opportunities in biotechnology.
- Moderate - Rising interest rates could increase the cost of capital for funding R&D…
- Watch on earnings: Clinical trial enrollment rates, Partnership revenue growth, Cash runway (months of operational funding remaining).
One Sentence Summary:
Protagonist Therapeutics: the story is balanced — clinical trial results for ptg-300 and other candidates.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
